Clinical Trial: Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer

U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06819007) titled 'Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer' on Feb. 05.

Brief Summary: This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.

Study Start Date: March 01

Study Type: INTERVENTIONAL

Condition: Ovarian Cancer

Intervention: DRUG: Trastuzumab Deruxtecan

T-DXd will...